Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Adherex is a biopharmaceutical company focused on cancer therapeutics. As of July 2009, the company announced a strategic pivot to focus remaining resources on the development of oral eniluracil (a DPD inhibitor to enhance 5-FU efficacy) and STS (a chemoprotectant against hearing loss from platinum-based chemotherapy). The company terminated its topical eniluracil study and returned ADH-1 patents to McGill University.
Key Financial Metrics
| Metric (in thousands USD) | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,012) | $(13,600) |
| Research & Development Expenses | $2,113 | $10,366 |
| General & Administrative Expenses | $1,214 | $3,520 |
| Cash and Cash Equivalents (Year End) | $685 | $5,401 |
| Working Capital | $412 | $3,209 |
| Accumulated Deficit | $(100,991) | $(97,979) |
| Net Cash Used in Operating Activities | $(4,688) | $(10,808) |
Debt and Liquidity: The company reported no long-term debt. Total liabilities were $427,000, primarily consisting of accounts payable and accrued liabilities. The company holds approximately $685,000 in cash, which management estimates is sufficient only through the second quarter of 2010.
Material Changes vs. Prior Period
- Significant Reduction in Loss: Net loss decreased by approximately $10.6 million (78%) compared to 2008, driven by a drastic reduction in operating expenses.
- R&D Expense Reduction: R&D expenses dropped by $8.2 million (80%) due to the closure of clinical studies and the termination of the topical eniluracil program.
- Impairment Charges: The company recorded a $386,000 impairment of capital assets and a $285,000 impairment of leasehold improvements in 2009, reflecting the decision to sell idle equipment and terminate the Maplewood facility lease.
- Management Turnover: Significant executive changes occurred in 2009, including the departure of the CEO, CFO, and several directors, replaced by new leadership in July and September 2009.
- Stock Delisting: Common stock was voluntarily delisted from the AMEX in January 2009 due to non-compliance with listing standards; it now trades on the Pink Sheets and TSX.
Guidance, Outlook, and Risks
Going Concern Uncertainty: The independent auditor's report includes a "going concern" qualification. Management states that without additional funding, operations may cease sooner than June 30, 2010. The company has not raised capital since February 2007.
Outlook:
- Eniluracil: Plans to design and implement a Phase II study combining oral eniluracil and 5-FU within 3-9 months, contingent on securing adequate financial resources.
- STS: Continuing Phase III trials with SIOPEL and COG to prevent hearing loss in pediatric patients. These trials are funded by the collaborators, with Adherex providing drug and safety monitoring.
- Capital Needs: Substantial additional funds are required immediately to continue operations beyond Q2 2010. Sources may include equity sales, debt, collaborations, or IP licensing.
Key Risks:
- Liquidity Risk: High risk of ceasing operations if capital cannot be raised in the near term.
- Development Risk: Product candidates are in clinical stages; prior trials for eniluracil by GSK were unsuccessful, though Adherex believes a new dosing strategy will succeed.
- Intellectual Property: Reliance on licensed IP from GSK and OHSU; patents for eniluracil expire in 2014/2015.
- Market Risk: Stock is subject to penny stock rules and low liquidity on the Pink Sheets.
Investor Verification Checklist
- Cash Runway: Verify current cash balance and burn rate to confirm if the company has extended operations beyond the projected Q2 2010 deadline.
- Financing Status: Check for recent press releases or filings regarding successful equity raises, debt financing, or strategic partnerships.
- Clinical Trial Progress: Confirm the status of the redesigned Phase II eniluracil study and patient enrollment rates for the STS Phase III trials.
- Stock Liquidity: Review trading volume on the Pink Sheets (ADHXF) and TSX (AHX) to assess the ability to exit positions.
- Management Stability: Monitor for further executive departures or changes in the Board of Directors.